ACADIA Pharmaceuticals Inc. (ACAD)
| Market Cap | 5.14B |
| Revenue (ttm) | 631.89M |
| Net Income (ttm) | -148.81M |
| Shares Out | 164.18M |
| EPS (ttm) | -0.92 |
| PE Ratio | n/a |
| Forward PE | 24.11 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,299,292 |
| Open | 31.70 |
| Previous Close | 31.39 |
| Day's Range | 31.15 - 31.80 |
| 52-Week Range | 15.54 - 33.99 |
| Beta | 0.59 |
| Analysts | Buy |
| Price Target | 32.72 (+4.5%) |
| Earnings Date | Feb 26, 2024 |
About ACAD
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company also develops Trofinetide, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome; Pimavanserin that is in Phase III AD... [Read more]
Financial Performance
In 2022, ACAD's revenue was $517.24 million, an increase of 6.83% compared to the previous year's $484.15 million. Losses were -$215.98 million, 28.7% more than in 2021.
Financial StatementsAnalyst Forecast
According to 18 analysts, the average rating for ACAD stock is "Buy." The 12-month stock price forecast is $32.72, which is an increase of 4.50% from the latest price.
News
Acadia Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, at 9:00 a....
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on December 13, 2023, the Compensation Committee of Acadia's Board of Directors (the “Committee”) granted in...
Delaware District Court Rules in Favor of Acadia on Formulation Patent Construction (Markman) Claims Regarding NUPLAZID® (pimavanserin)
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the U.S. District Court for the District of Delaware has issued a Claim Construction Order in favor of Acadi...
Delaware Federal District Court Rules in Favor of Acadia Pharmaceuticals in NUPLAZID® (pimavanserin) Patent Litigation
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the U.S. District Court for the District of Delaware has granted summary judgment to Acadia, confirming vali...
Acadia Pharmaceuticals Initiates Pivotal Phase 3 Study of Carbetocin (ACP-101) for the Treatment of Hyperphagia in Prader-Willi Syndrome
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the initiation of the Phase 3 COMPASS PWS study evaluating the efficacy and safety of carbetocin nasal spray (ACP...
Acadia Pharmaceuticals Initiates Phase 2 Clinical Trial of ACP-204 for the Treatment of Alzheimer's Disease Psychosis
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the initiation of a Phase 2 study evaluating the efficacy and safety of ACP-204 for the treatment of hallucinatio...
Acadia Pharmaceuticals Announces Change in Research and Development Leadership
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Doug Williamson, M.D., Executive Vice President, Head of Research and Development, will be leaving the compa...
Acadia Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operating Overview
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the third quarter ended September 30, 2023. “In the third quarter, Acadia delivered rec...
Acadia Pharmaceuticals to Participate in the Guggenheim Securities 5th Annual Inflammation & Immunology Conference
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in the Guggenheim Securities 5th Annual Inflammation & Immunology (I&I) Conference on Tu...
Acadia Pharmaceuticals Announces the Rett Sibling Scholarship Program
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the establishment of the Rett Sibling Scholarship, sponsored by Acadia to shine a light on the impact of Rett syn...
Acadia Pharmaceuticals to Announce Third Quarter Financial Results on November 2, 2023
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report third quarter financial results on Thursday, November 2, 2023, after the close of the U.S. fi...
Acadia stock price analysis: ACAD risk/reward is attractive
Acadia Pharmaceuticals (NASDAQ: ACAD) stock price did well on Wednesday even as American equities retreated. The biotech stock jumped to a high of $26.15, much higher than this week's low of $22.95.
Acadia Pharmaceuticals Appoints Albert Kildani as Senior Vice President, Investor Relations and Corporate Communications
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Albert Kildani as Senior Vice President, Investor Relations and Corporate Communications. Mr. ...
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at the following upcoming investor conferences: Citi's 18th Annual BioPharma Conference ...
SHAREHOLDER ALERT: Kaskela Law LLC Announces Shareholder Lawsuit Against Acadia Pharmaceuticals, Inc. (NASDAQ: ACAD) and Encourages Long-Term ACAD Investors to Contact the Firm
PHILADELPHIA , Aug. 16, 2023 /PRNewswire/ -- Kaskela Law LLC announces that a shareholder class action lawsuit has been filed against Acadia Pharmaceuticals Inc. ("Acadia") (NASDAQ: ACAD) on behalf of...
Acadia Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operating Overview
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the second quarter ended June 30, 2023. “Our second quarter 2023 results reflect strong...
Acadia Pharmaceuticals Appoints Kevin R. Oliver, Ph.D.
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced today the appointment of Dr. Kevin R. Oliver as Senior Vice President, Chief Business Officer, effective July 10, 2023....
Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 2, 2023
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report second quarter financial results on Wednesday, August 2, 2023, after the close of the U.S. fi...
Acadia Pharmaceuticals: A Mid-Cap Biotech Making Large Moves
Shares of ACADIA Pharmaceuticals Inc. NASDAQ: ACAD jumped nearly 25% on Friday after the San Diego-based company announced preliminary second-quarter results and a pivotal acquisition. The gain was th...
Acadia stock rallies on drug news as Roivant also climbs, while Leslie's, Theseus shares plunge and more moving stocks
Acadia Pharmaceuticals Inc.'s stock ACAD, -0.23% surged 18% in premarket trading after the company expanded drug rights to a treatment for a rare neurological disorder.
Acadia Pharmaceuticals stock rockets 30% following expanded drug rights
Acadia Pharmaceuticals Inc. ACAD, -0.23% shares rallied in the extended session Thursday after the drug maker said it expanded its rights to a treatment for a rare neurological disorder. Acadia shares...
Acadia Pharmaceuticals Acquires Ex-North American Rights to Trofinetide and Global Rights to Neuren's NNZ-2591 in Rett Syndrome and Fragile X Syndrome
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) today announced that it has expanded its current licensing agreement for trofinetide with Neuren Pharmaceuticals to acquire ex-No...
Acadia Pharmaceuticals Announces Phase 3 Development Candidate ACP-101 (intranasal carbetocin) for Prader-Willi Syndrome
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the addition of a new Phase 3 development candidate to its rare disease portfolio, ACP-101 (intranasal carbetocin...
Nature Medicine Publishes Results from Pivotal Phase 3 LAVENDER™ Study Evaluating DAYBUE™ (trofinetide) Efficacy and Safety in Patients with Rett Syndrome
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Nature Medicine published results from the pivotal Phase 3 LAVENDER™ trial, a 12-week randomized, double-bli...
Acadia Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the Jefferies Global Healthcare Conference on Wednesday, June 7, 2023 at 10:00 a.m. Easte...